20/20 Biolabs Inc (AIDX) Stock Price & News

Analyst	Recommendation	Action	Price target	Projected	Date
Michael Okunewitch Maxim Group	Buy	Reiterated	-	-	10/02/2026
Brian Kinstlinger Alliance Global Partners	Buy	Maintained	2,00 CAD	+426,3%	05/08/2026
Justin Keywood Stifel Nicolaus	Buy	Maintained	2,50 CAD	+557,9%	03/20/2026

All values in USD	2025-ж. сен.	2025-ж. дек.	2026-ж. мар.	2026-ж. июн.
Revenue	417,98 миң	538,27 миң	353,38 миң	730,57 миң
Cost of goods sold	272,91 миң	407,86 миң	290,49 миң	425,84 миң
Cost of revenue	272,91 миң	407,86 миң	290,49 миң	425,84 миң
Research and development expenses	131,06 миң	130,55 миң	153,48 миң	257,63 миң
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	814,18 миң	912,71 миң	1,35 млн	1,29 млн
Operating expense	945,24 миң	1,04 млн	1,51 млн	1,55 млн
Total operating expenses	1,22 млн	1,45 млн	1,80 млн	1,97 млн
Operating income	-800,17 миң	-912,85 миң	-1,44 млн	-1,24 млн
Other non operating income	-	-273,03 миң	-471,12 миң	-4,35 миң
EBT including unusual items	-825,54 миң	-1,31 млн	-2,17 млн	-1,51 млн
EBT excluding unusual items	-825,54 миң	-1,31 млн	-2,17 млн	-1,51 млн
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-825,54 миң	-1,31 млн	-2,17 млн	-1,51 млн
Net profit margin	-197,51%	-242,96%	-615,45%	-206,19%
Earnings per share	-	-	-	-
Interest and investment income	4,18 миң	3,09 миң	6,65 миң	14,48 миң
Interest expense	-29,55 миң	-124,98 миң	-267,01 миң	-272,24 миң
Net interest expenses	-25,37 миң	-121,90 миң	-260,36 миң	-257,77 миң
Depreciation and amortization charges	-	-	-	-
EBITDA	-779,11 миң	-892,71 миң	-1,43 млн	-1,22 млн
Gain or loss from assets sale	-	-	-	-

Finance